Cytarabine
Near Add Your Location
Accepting patients
Cladribine, Cytarabine and Venetoclax for HR-MDS
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
- Has results
Accepting patients
Venetoclax Plus Intensive Chemotherapy
Phase 1B Study of Venetoclax in Combination With Standard Intensive Chemotherapy With Daunorubicin Plus Cytarabine Followed by High-Dose Cytarabine in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia and Advanced Myelodysplastic Syndrome
- BCL-2 Inhibitor
- Chemotherapy
- Phase 1
Accepting patients
A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
Accepting patients
Cytarabine Alternating with Decitabine
Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- Hypomethylating Agents (HMA)
- Phase 2
Accepting patients
Chemotherapy Plus Venetoclax
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
- BCL-2 Inhibitor
- Kinase Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
Accepting patients
Gemtuzumab as Part of Chemotherapy
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
- Antibody Drug Conjugate (ADC)
- Hypomethylating Agents (HMA)
- White Blood Cell Stimulant
- CD33
- Phase 2
Accepting patients
Heart Protection w/Dexrazoxane During Chemotherapy
Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms
- Chemotherapy
- Phase 2
Accepting patients
Venetoclax w/ Combination Chemotherapy
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
- BCL-2 Inhibitor
- Chemotherapy
- Phase 1/2
Accepting patients
CPX-351 (VYXEOS)
A Prospective, Single Site, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
- Allogeneic Stem Cell Transplant
- Chemotherapy
- Steroid
- Phase 2
Accepting patients
PVEK (IMGN632)
Phase 1 Study of FLAG-Ida With Pivekimab Sunirine (PVEK [IMGN632]) for Adults With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
- Antibody Drug Conjugate (ADC)
- CD123
- Phase 1